Pace of Monjuvi’s growth may dictate how quickly MorphoSys can rebuild its pipeline
MorphoSys plans to aggressively expand Monjuvi, but has holes to fill in early stage pipeline
MorphoSys plans to leverage its more than $1 billion in cash and future Monjuvi revenues to rebuild its pipeline.
MorphoSys’ first marketed therapeutic, Monjuvi, has the makings of a blockbuster, but the company and partner Incyte will need to execute on the drug’s launch and planned label expansions to generate the cash flows needed to rebuild MorphoSys’ early-stage pipeline.
According to CEO Jean-Paul Kress, the near-term future and value of MorphoSys AG (Xetra:MOR; NASDAQ:MOR) are inextricably tied to the potential of Monjuvi tafasitimab-cxix in a range of hematologic cancers.
“Our ambition is to build a cornerstone in DLBCL as well as other indications,” Kress told BioCentury. “I will always come back to Monjuvi because it is a huge portion of our future.”
So far, data from the anti-CD19 mAb in relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) suggest its market potential is high. Monjuvi was approved in July based on data from